Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02810457. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Study identification
- NCT ID
- NCT02810457
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 731 participants
Conditions and interventions
Conditions
Interventions
- FKB238 (bevacizumab) Drug
- Avastin (bevacizumab) Drug
- Paclitaxel Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 6, 2016
- Primary completion
- Jan 23, 2019
- Completion
- Jan 25, 2022
- Last update posted
- Mar 9, 2022
2016 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 7814 - Compassionate Care Research Group | Fountain Valley | California | 92708 | — |
| Research Site 7811 - Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Research Site 7803 - 21st Century Oncology | Jacksonville | Florida | 32204 | — |
| Research Site 7812 - Joliet Oncology-Hematology Associates, Ltd. | Joliet | Illinois | 60435 | — |
| Research Site 7810 - Edward H. Kaplan, MD and Associates | Skokie | Illinois | 60076 | — |
| Research Site 7813 - Trinity Cancer Care Center | Minot | North Dakota | 58701 | — |
| Research Site 7805 - Hematology & Oncology Associates, Inc. | Canton | Ohio | 44708 | — |
| Research Site 7801 - Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Research Site 7804 - Tri-County Hematology & Oncology Associates, Inc. | Massillon | Ohio | 44646 | — |
| Research Site 7809 - Millennium Oncology | Houston | Texas | 77090 | — |
| Research Site 7806 - Vista Oncology Inc. PS | Olympia | Washington | 98502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 136 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02810457, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2022 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02810457 live on ClinicalTrials.gov.